

Table S1. General characteristics of the 48 patients that switched from IL17 to IL23 inhibitors and the PASI score trend from baseline to 52 weeks.

No. of patients	Age	Sex	BMI	Age of onset	Type of psoriasis	PSA	Biologicals in course	Previous biological therapy	PASI baseline	PASI 16 weeks	PASI 90 16 weeks	PASI 100 16 weeks	PASI 128 weeks	PASI 90 28 weeks	PASI 100 28 weeks	PASI 48 weeks	PASI 100 48 weeks	PASI 100 48 weeks	Follow up (months)	Cause of IL17 inhibitors suspension	Obesity	Cardiovascular disease	Diabetes mellitus
1	62	m	27	47	vulgar	no	risankizumab	adalimumab ixekizumab	9	3	no	no	NA	NA	NA	NA	NA	NA	8		no	yes	no
2	61	m	28	20	vulgar	yes	risankizumab	adalimumab, certolizumab, secukinumab	6	6	no	no	NA	NA	NA	NA	NA	NA	3	primary inefficacy	no	no	no
3	65	f	26	24	vulgar	yes	risankizumab	adalimumab, etanercept, certolizumab, ixekizumab	15	0	yes	yes	0	yes	yes	NA	NA	NA	9		no	yes	no
4	67	f	27	47	vulgar	no	risankizumab	adalimumab, etanercept, infliximab, ixekizumab	11	0	yes	yes	0	yes	yes	0	yes	yes	14		no	no	no
5	78	f	35	23	vulgar	no	risankizumab	adalimumab, etanercept, ixekiumab	16	5	no	no	NA	NA	NA	NA	NA	NA	6		yes	yes	no
6	60	m	30	23	vulgar	no	guselkumab	adalimumab, etanercept, secukinumab	10	NA	NA	NA	4	no	no	3	no	no	18		yes	NA	NA
7	67	f	43	27	vulgar	no	risankizumab	adalimumab, infliximab, ixekizumab, brodalumab	19	1.5	yes	no	1.5	yes	no	NA	NA	NA	10		yes	yes	yes
8	57	f	26	47	vulgar	yes	tildrakizumab	adalimumab, ixekizumab	11	0	yes	yes	0	yes	yes	0	yes	yes	NA		no	NA	NA
9	65	m	29	41	vulgar	no	risankizumab	adalimumab, ixekizumab, brodalumab	17	1.5	yes	no	0	yes	yes	NA	NA	NA	11		no	yes	yes
10	53	m	23	44	vulgar	no	guselkumab	adalimumab, secukinumab	12	3	no	no	1	yes	no	1	yes	no	15		no	NA	NA
11	58	m	25	49	vulgar	no	risankizumab	adalimumab, secukinumab	8	4	no	no	0	yes	yes	NA	NA	NA	10		no	yes	no
12	54	m	26	37	vulgar	no	risankizumab	adalimumab, secukinumab, ixekizumab, brodalumab	8	3	no	no	1.5	yes	no	NA	NA	NA	11		no	yes	no
13	42	m	24	15	vulgar	yes	guselkumab	adalimumab, ustekinumab, ixekizumab	10.8	6	no	no	5	no	no	0	yes	yes	21		no	NA	NA
14	58	m	37	38	vulgar	yes	guselkumab	adalimumab, ustekinumab, secukinumab	22	2	yes	no	0.5	yes	no	0	yes	yes	21		yes	yes	yes

15	41	f	22	26	vulgar	no	risankizu mab	adalimumab, ustekinumab, secukinumab	7	2	no	no	NA	NA	NA	NA	NA	NA	8		no	NA	NA
16	65	f	26	22	erythr ode rmic	no	guselkum ab	adalimumab,etanercept,inflximab, ustekinumab, ixekizumab	30	16.	no	no	8	no	no	7	yes	no	14	lack of efficacy	no	NA	NA
17	42	m	28	34	vulgar	no	risankizu mab	brodalumab	8	0	yes	yes	0	yes	yes	0	yes	yes	13		no	no	no
18	72	f	22	54	vulgar	no	risankizu mab	etanercept secukinumab	6	3	no	no	3	no	no	5	no	no	13		no	no	no
19	58	m	23	36	vulgar	yes	guselkum ab	etanercept, infliximab, ixekizumab	5	3	no	no	3	no	No	3	no	no	23		no	yes	no
20	53	m	27	23	vulgar	no	risankizu mab	etanercept, ixekizumab	10	4	no	no	1	yes	No	1	yes	no	14		no	yes	no
21	51	m	23	26	vulgar	no	risankizu mab	infliximab, ustekinumab, secukinumab	8	1.5	yes	no	1.5	yes	No	NA	NA	NA	9		no	yes	no
22	46	m	35	34	vulgar	no	risankizu mab	ixekizumab	0	0	yes	yes	NA	NA	NA	NA	NA	NA	8		yes	yes	no
23	70	f	19	45	vulgar	no	risankizu mab	ixekizumab	9	2	no	no	NA	NA	NA	NA	NA	NA	8		no	yes	no
24	65	m	25	53	vulgar	no	risankizu ma	ixekizumab	10	1.5	no	no	NA	NA	NA	NA	NA	NA	8		yes	yes	no
25	74	f	24	74	vulgar	no	guselkum ab	ixekizumab	12	0	yes	yes	0	yes	yes	0	yes	yes	22		no	NA	NA
26	62	m	27	46	vulgar	no	risankizu mab	ixekizumab	8	15	no	no	NA	NA	NA	NA	NA	NA	5	primary ineffica cy	no	yes	no
27	73	m	23	50	vulgar	no	risankizu mab	ixekizumab	17	1.5	yes	no	NA	NA	NA	NA	NA	NA	9		no	yes	no
28	65	f	25	4	vulgar	yes	guselkum ab	ixekizumab	7	8	no	no	NA	NA	NA	NA	NA	NA	4	primary ineffica cy	no	no	no
29	46	m	28	35	vulgar	no	guselkum ab	ixekizumab	11	0	yes	yes	0	yes	yes	0	yes	yes	17		no	NA	NA
30	35	m	20	9	vulgar	no	guselkum ab	ixekizumab	12	0.5	yes	no	0	yes	yes	0	yes	yes	18		no	NA	NA
31	42	m	35	3	guttate	no	risankizu mab	ixekizumab	10	3	no	no	NA	NA	NA	NA	NA	NA	7		no	no	no
32	43	f	25	41	vulgar	yes	risankizu mab	ixekizumab, brodalumab	16	10	no	no	7	no	no	NA	NA	NA	8	primary ineffica cy	no	yes	no

33	67	m	27	45	vulgar	no	risankizu mab	ixekizumab, brodalumab	30	12	no	no	8	no	no	NA	NA	NA	10		no	yes	no
34	75	m	41	50	vulgar	no	risankizu mab	ixekizumab, brodalumab	18	NA	NA	NA	NA	NA	NA	NA	NA	NA	1		yes	yes	no
35	67	f	28	60	inverse	no	tildrakizu mab	secukinumab	7	0	yes	yes	0	yes	yes	0	yes	yes	9		no	yes	no
36	71	f	20	54	vulgar	no	tildrakizu mab	secukinumab	17	1.5	yes	no	0	yes	yes	0	yes	yes	9		no		
37	77	m	30	68	vulgar	no	risankizu mab	secukinumab	8	1.5	no	no	1.5	no	no	0	yes	yes	12		no	yes	yes
38	53	m	23	21	vulgar	no	guselkum ab	secukinumab	13	6.5	no	no	3.5	no	no	7	no	no	22		no	NA	NA
39	59	m	36	54	vulgar	no	risankizu mab	secukinumab	8	6	no	no	6	no	no	NA	NA	NA	8	primary ineffica cy	yes	no	no
40	55	m	27	36	vulgar	no	risankizu mab	secukinumab	10	6	no	no	3	no	no	NA	NA	NA	11		no	yes	no
41	44	f	24	38	vulgar	no	risankizu mab	secukinumab	6	0	yes	yes	0	yes	yes	NA	NA	NA	11		no	yes	no
42	32	m	19	17	vulgar	no	guselkum ab	secukinumab	5.5	0	yes	yes	0	yes	yes	0	yes	yes	16		no		
43	22	f	23	8	vulgar	no	risankizu mab	secukinumab brodalumab	10	3	no	no	NA	NA	NA	NA	NA	NA	7		no	no	no
44	27	m	30	12	vulgar	no	risankizu mab	secukinumab ustekinumab	15	0	yes	yes	0	yes	yes	NA	NA	NA	13		no	no	no
45	50	m	28	26	vulgar	no	guselkum ab	secukinumab, ixekizumab	6	1.5	yes	no	6	no	no	NA	NA	NA	7	primary ineffica cy	no	NA	NA
46	48	m	26	28	vulgar	no	risankizu mab	ustekinumab secukinumab	9	1.5	yes	no	NA	NA	NA	NA	NA	NA	7		no	no	no
47	53	f	26	49	guttate	no	risankizu mab	ustekinumab, ixekizumab	17	1.5	yes	no	1.5	yes	no	0	yes	yes	13		no	no	no
48	64	m	34	50	vulgar	no	guselkum ab	ustekinumab, secukinumab	17	5	no	no	3	no	no	3	no	No	16		yes	NA	NA